Basic and clinical studies on ritipenem acoxil in urinary tract infection

Noriaki Ono, Ryuuji Fujita, Toyohiko Watanabe, Tadasu Takenaka, Kouichi Monden, Koushi Sakuramoto, Toshihide Hayashi, Kazuhiro Hata, Yoshitsugu Nasu, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Katsuyoshi Kondo, Teruhisa Ohhashi, Teruaki Akaeda, Yasuhiro Katayama

Research output: Contribution to journalArticlepeer-review


We studied the antibacterial activity and clinical efficacy of ritipenem acoxil (RIPM-AC), a neworal penem antibiotic, in urinary tract infections. 1) Antibacterial activity: We measured the MICs of ritipenem (RIPM) against 210 clinicalisolates of 14 species from urinary tract infections and compared them with those of cefaclor (CCL), cefixime (CFIX) and cefotiam (CTM). Against gram-positive organisms, the overallantibacterial activity of RIPM was superior to that of other antibiotics. Against gram-negativeorganisms, the activity of RIPM was almost equivalent to that of other antibiotics. 2) Clinical efficacy: Four patients with acute uncomplicated cystitis (AUC) and 30 patients withchronic complicated urinary tract infection were treated with ritipenem acoxil. According to thecriteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100%(2/2) for AUC and 85.7%(24/28) for chronic complicated UTI. Bacteriologically, 28 of 32 strains (87.5%) wereeradicated. 3) Side effects: No side effects were observed. Abnormal laboratory findings, however, wereobserved in 2 cases, one with slight elevations of GOT and GPT and the other with decreases in RBC, Hb and Ht.

Original languageEnglish
Pages (from-to)256-263
Number of pages8
JournalJapanese Journal of Chemotherapy
Publication statusPublished - Jan 1 1995


  • ritipenem acoxil

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Basic and clinical studies on ritipenem acoxil in urinary tract infection'. Together they form a unique fingerprint.

Cite this